WO2006038318A1 - Gingivitis remedial or preventive agent - Google Patents

Gingivitis remedial or preventive agent Download PDF

Info

Publication number
WO2006038318A1
WO2006038318A1 PCT/JP2005/003868 JP2005003868W WO2006038318A1 WO 2006038318 A1 WO2006038318 A1 WO 2006038318A1 JP 2005003868 W JP2005003868 W JP 2005003868W WO 2006038318 A1 WO2006038318 A1 WO 2006038318A1
Authority
WO
WIPO (PCT)
Prior art keywords
gingivitis
agent
streptococcus mutans
disintegrating
weight
Prior art date
Application number
PCT/JP2005/003868
Other languages
French (fr)
Japanese (ja)
Inventor
Yasufumi Itaya
Original Assignee
Kobayashi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co., Ltd. filed Critical Kobayashi Pharmaceutical Co., Ltd.
Publication of WO2006038318A1 publication Critical patent/WO2006038318A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/986Milk; Derivatives thereof, e.g. butter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Definitions

  • the present invention relates to a gingivitis improving agent or preventive agent.
  • the gingivitis improving agent or preventive agent of the present invention contains an antibody against Streptococcus mutans and a disintegrating abrasive.
  • gingivitis The major cause of gingivitis is plaque. Plaque adheres directly to the periodontal tissues such as gums and gums, causing inflammation, and also adheres to the tooth surface. The acid produced in the plaque on the tooth surface decalcifies the tooth enamel, causes decoration, and gingivitis is caused by the progress of decoration. In other words, in order to improve and prevent gingivitis, it is necessary to remove not only periodontal tissue but also dental plaque.
  • Patent Document 1 Specification of British Patent No. 1505513
  • the present invention has been made in view of the circumstances as described above, and is suitable for use by patients with gingivitis and can easily prevent gingivitis in non-patients. I will provide a.
  • the present invention provides the following.
  • a gingivitis ameliorating agent or preventive agent comprising an antibody against a whole cell or a cell component of Streptococcus mutans and a disintegrating abrasive.
  • a gingivitis ameliorating agent or preventive agent comprising a colostrum colostrum composition immunized with whole cells or components of Streptococcus mutans and a disintegrating abrasive.
  • the cell component is a cell wall fraction, a fibrous structure fraction, a pilus component fraction, a darcosyltransferase fraction, a protein antigen fraction, or a combination thereof of Streptococcus mutans, (2 ) Or (3) gingivitis improving agent or preventive agent.
  • Streptococcus mutans is a human-type Streptococcus mutans or a mutant thereof, and its serotype is c, d, e, f, or g, (1) one of (4) An agent for improving or preventing gingivitis.
  • the gingivitis improving agent or preventive agent of the present invention comprises an antibody against a whole cell or a cell component of Streptococcus mutans and a disintegrating abrasive.
  • Streptococcus mutans bacteria include mutants.
  • the antibody against the whole cell or cell component of Streptococcus mutans can be produced by various known production methods, whether it is a polyclonal antibody or a monoclonal antibody.
  • an animal may be immunized with all or a cell component of Streptococcus mutans, and an antibody may be obtained from the secretion or tissue of the animal.
  • a preferred composition containing the antibody includes a composition obtained from breast milk of rush immunized using whole cells or components of Streptococcus mutans as an antigen. Among them, a colostrum composition is preferable.
  • colostrum refers to milk collected within 24 hours after delivery
  • colostrum composition is a composition separated from the colostrum, obtained by processing the colostrum. Composition, and colostrum itself. Immunization of animals such as sushi is carried out using whole cells or components of Streptococcus mutans within one to three months before delivery.
  • the colostrum composition may be liquid or solid.
  • the solid composition include those obtained by converting colostrum into a powder form by freeze drying.
  • formulation methods can be used for the production method of the colostrum composition.
  • the colostrum composition is considered to have an effect of activating the skin in the oral cavity as well as preventing and reducing plaque accumulation.
  • serotypes preferred by human Streptococcus mutans and mutants thereof are c-types present in the oral cavity of people who prefer c, d, e, f, or g type strains. More preferably, the strain belongs to.
  • Streptococcus mutans may be subjected to various known cultures and pretreatments.
  • an externally dialyzed solution of BHI medium can be used as the medium, and the grown bacteria can be washed and then treated with formalin.
  • Examples of the bacterial cell component include a cell wall fraction, a fibrous structure fraction, a pilus component fraction, a gnolecosyltransferase (GTF) fraction, a protein antigen fraction, and combinations thereof. Each fraction can be obtained by various known methods.
  • the amount of colostrum composition relative to the total weight of the gingivitis improving agent or preventive agent is 0.01 wt% or more, preferably 1 wt% or more, more preferably 2 wt% or more. In Therefore, it is 30 wt% or less, preferably 20 wt% or less. If it is less than the above range, the effect of colostrum may not be sufficiently obtained, and if it exceeds the above range, it is not economical.
  • the gingivitis improving or preventing agent of the present invention contains a disintegrating abrasive.
  • the disintegrating abrasive refers to an abrasive whose average particle diameter decreases when it is subjected to polishing under a load. Disintegrating abrasives not only remove plaque without excessively irritating and abrading the gums and gums, but can also enhance the expression of antibody effects.
  • Materials for the disintegrating abrasive include crystalline silica gel, dibasic calcium phosphate dihydrate, dibasic calcium phosphate, anhydrous, monobasic calcium phosphate, tribasic calcium phosphate, calcium carbonate, calcium pyrophosphate, insoluble metaphosphate
  • Examples include sodium, aluminosilicate, aluminum oxide, aluminum hydroxide, tribasic magnesium phosphate, magnesium carbonate, magnesium sulfate, titanium oxide, and carbon. These may be used alone or in combination of two or more. These materials are preferably porous.
  • the initial average particle size of the disintegrating abrasive is preferably in the range of 9 1 100 / im.
  • the average particle size after polishing under load is not particularly limited, and is selected according to the use mode of the agent of the present invention.
  • the average particle size and the particle size distribution are expressed as values measured based on laser diffraction and laser scattering methods. “Brushing at a load of 600 g” means that 0.5 g of the agent of the present invention is applied to a toothbrush and brushing is performed with a load of 600 g under the condition of a 300 mm width and 200 strokes per minute. .
  • the amount of the disintegrating abrasive with respect to the total weight of the gingivitis improving agent or preventive agent is 5 wt% or more, preferably 10 wt ° / o , 95 wt% or less, preferably 60 wt% or less.
  • the disintegrating abrasive is considered to bring about an excellent effect by gradually disintegrating in the process of using a load. That is, when a gingivitis improving agent or preventive agent is used as a toothpaste, since it has a relatively large particle size at the start of toothbrushing, large dirt can be efficiently removed. Continue brushing teeth However, when fine particles become dirty, the particles become disintegrated under load and the particle size becomes small, so that the shape becomes effective for removing fine particles. Thus, the change in particle size over time is useful for removing dirt and plaque in the mouth.
  • the disintegrating abrasive is porous, the particles will disintegrate and the specific surface area will increase if you continue brushing your teeth, so that you can efficiently absorb and remove dirt, plaque, malodorous components, pigments, etc. in the oral cavity. .
  • the gingivitis ameliorating agent or preventive agent of the present invention includes other components effective for removing plaque within a range not inhibiting the effects of the present invention; carriers such as gelling agents and solvents; surfactants; It contains various known ingredients such as coloring materials, coloring agents, fragrances, preservatives, and the like.
  • Active ingredients other than antibodies and disintegrating abrasives include allantoin, ⁇ -monoaminocaproic acid, tranexamic acid, azulene, vitamins such as vitamin C and sputum, and herbal medicine extracts.
  • Gelling agents include sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylhydroxyethylcellulose, hydroxyethylcellulose, sodium alginate, carrageenan, gum arabic, xanthan gum, tragacanth gum, carragham gum, polyvinyl alcohol, polyacrylic. Examples thereof include sodium acid, carboxybinole polymer, and polybulurpyrrolidone.
  • the content of the gelling agent is usually 0.3-5 wt% with respect to the total weight of the agent of the present invention.
  • Examples of the solvent include water and ethanol.
  • Surfactants include anionic, nonionic, cationic, and zwitterionic surfactants.
  • Examples of the sweetener include sweeteners such as saccharin sodium, stevioside, neohesperidyl dihydrochalcone, glycyrrhizin, perilartine, and p-methoxycinnamic aldehyde.
  • Examples of the fragrances include essential oils such as peppermint and spearmint, 1 menthol, carvone, eugenol, and vanitol.
  • the dosage form of the gingivitis improving agent or the preventive agent of the present invention is not particularly limited.
  • the solution may be in the form of a solid preparation such as a cream, paste, tablet, capsule, powder, granule or the like. It may be in the form of a liquid agent such as a suspension or emulsion.
  • the gingivitis improving agent or preventive agent according to the present invention includes dentifrice such as toothpaste, powder dentifrice, liquid dentifrice, etc .; mouthwash; intraoral pasta; gingival massage cream; It is provided in various forms such as tablets; lozenges; foods such as chewy / fungam, ice cream and whipped cream.
  • the amount of colostrum composition and disintegrating abrasive, and Other types and amounts of ingredients are selected.
  • the gingivitis improving agent or the preventive agent of the present invention is stored in an appropriate container according to the dosage form and is used.
  • the gingivitis improving agent or preventive agent of the present invention is a solid agent, for example, when it is in the form of a toothpaste, a toothpaste, a massage cream, etc.
  • the shape of a plastic tube, an aluminum foil laminate tube or the like is variable as a preferable container.
  • the gingivitis improving agent or preventive agent of the present invention is a liquid agent, for example, in the case of liquid dentifrice or mouthwash, it may be contained in a plastic container such as a PET container.
  • a light-shielding container is preferable.
  • the pH is not necessarily limited, but is typically pH 4 or higher, preferably 5 or higher, more preferably 5. It is 5 or more, 10 or less, preferably 9 or less, more preferably 7.5 or less.
  • a paste having the following composition was prepared.
  • the antibody contained in colostrum was used, and disintegrating silica gel was used as a disintegrating abrasive.
  • Colostrum composition was obtained by pulverizing ushi milk collected within 24 hours after delivery by freeze-drying. Usushi was previously immunized with Streptococcus mutans.
  • Colostrum composition 10.0% by weight
  • Disintegrating silica gel (initial average particle size at the time of preparation: 30 ⁇ m,
  • Polyoxyethylene polyoxypouylene block copolymer (average molecular weight)
  • a paste having the following composition was prepared in the same manner as in Example 1 except that the colostrum and adult composition was changed to a component derived from normal ushi milk that was not immunized with Streptococcus mutans. .
  • Disintegrating silica gel (initial average particle size at the time of preparation: 30 ⁇ m,
  • Polyoxyethylene polyoxypouylene block copolymer (average molecular weight)
  • a paste having the following composition was prepared in the same manner as in Comparative Example 1 except that the disintegrating silica gel was changed to a hardly disintegrating silica gel.
  • Hardly disintegrating silica gel (initial average particle size at the time of preparation: 30 / m) 10.0% by weight polyoxyethylene polyoxypropylene block copolymer (average molecular weight)
  • a paste having the following composition was prepared in the same manner as in Example 1 except that the disintegrating silica gel was changed to a hardly disintegrating silica gel.
  • Colostrum composition 10.0% by weight
  • Polyoxyethylene polyoxypouylene block copolymer (average molecular weight)
  • the gingivitis improving or preventing agent of the present invention exhibits excellent performance.
  • the effect of improving or preventing gingivitis is improved as compared with the case where each is used alone. Can be improved. Furthermore, the agent for improving or preventing gingivitis of the present invention is suitable for long-time use because there is little irritation to the affected area even when used by gingivitis patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

[PROBLEMS] To provide an agent capable of easy and effective remedy or prevention of gingivitis, realizing reduced irritation on gingivitis affected parts. [MEANS FOR SOLVING PROBLEMS] Easy and effective remedy or prevention of gingivitis can be attained by the use of an agent comprising a disintegration abrasive and an antibody against whole bacterial cells, or bacterial cell constituents, of Streptococcus mutans. The antibody can be obtained from the foremilk of cow immunized with whole bacterial cells, or bacterial cell constituents, of Streptococcus mutans.

Description

明 細 書  Specification
歯肉炎改善剤又は予防剤  Gingivitis improving agent or preventive agent
技術分野  Technical field
[0001] 本発明は、歯肉炎改善剤又は予防剤に関する。本発明の歯肉炎改善剤又は予防 剤は、ストレプトコッカス'ミュータンス菌に対する抗体と崩壊性研磨剤とを含む。 背景技術  [0001] The present invention relates to a gingivitis improving agent or preventive agent. The gingivitis improving agent or preventive agent of the present invention contains an antibody against Streptococcus mutans and a disintegrating abrasive. Background art
[0002] 近年、歯肉炎の患者が増加しており、その改善及び予防が求められている。歯肉 炎の主な原因としては、歯垢が挙げられる。歯垢は歯茎や歯肉等の歯周組織に直接 付着して炎症を起こすだけでなぐ歯面にも付着する。歯面上の歯垢内で生成した 酸は歯のエナメル質を脱灰し、う飾を引き起こし、う飾の進行によって歯肉炎に至る。 つまり、歯肉炎の改善及び予防には、歯周組織だけでなく歯面の歯垢も除去する必 要がある。  [0002] In recent years, the number of patients with gingivitis has increased, and improvement and prevention thereof have been demanded. The major cause of gingivitis is plaque. Plaque adheres directly to the periodontal tissues such as gums and gums, causing inflammation, and also adheres to the tooth surface. The acid produced in the plaque on the tooth surface decalcifies the tooth enamel, causes decoration, and gingivitis is caused by the progress of decoration. In other words, in order to improve and prevent gingivitis, it is necessary to remove not only periodontal tissue but also dental plaque.
[0003] しかし、歯肉炎の患者が従来の歯磨き剤で口中を洗浄しょうとすると、患部が刺激 されて痛みを伴い、歯垢を充分に除去することは困難である。さらに、歯磨き剤に含 まれる研磨剤で歯茎を痛めて歯肉炎を悪化させることもある。従って、従来の歯磨き 剤では、歯肉炎の改善及び予防が充分に行われているとはいえない。  [0003] However, when a patient with gingivitis tries to clean the mouth with a conventional dentifrice, the affected area is stimulated and painful, and it is difficult to sufficiently remove plaque. In addition, abrasives contained in dentifrices may damage gums and exacerbate gingivitis. Therefore, it cannot be said that conventional dentifrices have sufficiently improved and prevented gingivitis.
[0004] 歯垢は、その約 70%が細菌、約 20%が細菌により形成された多糖及び約 10%が 食物残渣と考えられている。歯垢の形成は、ストレプトコッカス'ミュータンス菌を主成 分とする口腔内細菌がショ糖から多糖を合成することによって進行するとされる。その 一方、ストレプトコッカス'ミュータンス全菌体をゥシに免疫することによって得られる母 乳は、該菌の抗体を含有すると考えられる。そこで、この母乳を使用して、ストレブトコ ッカス'ミュータンス菌の口腔内への定着を抑制し、う飾を防止する方法が報告されて いる(特許文献 1を参照)。しかし、この方法は、歯肉炎の改善及び予防に充分な効 果を発揮してレ、るとはレ、えなレ、。  [0004] About 70% of dental plaque is considered to be bacteria, about 20% are polysaccharides formed by bacteria, and about 10% are food residues. Plaque formation is caused by oral bacteria, mainly composed of Streptococcus mutans bacteria, synthesizing polysaccharides from sucrose. On the other hand, it is considered that breast milk obtained by immunizing mice with whole cells of Streptococcus mutans contains antibodies of the bacteria. Thus, a method has been reported in which this breast milk is used to suppress the colonization of Streptococcus mutans bacteria in the oral cavity and prevent decoration (see Patent Document 1). However, this method is effective for improving and preventing gingivitis.
特許文献 1 :英国特許第 1505513号明細書  Patent Document 1: Specification of British Patent No. 1505513
発明の開示  Disclosure of the invention
発明が解決しょうとする課題 [0005] 本発明は上記のような事情に鑑みなされたものであり、歯肉炎の患者の使用に適し 、非患者において歯肉炎の予防を簡便に行うことが出来る、歯肉炎改善剤又は予防 剤を提供する。 Problems to be solved by the invention [0005] The present invention has been made in view of the circumstances as described above, and is suitable for use by patients with gingivitis and can easily prevent gingivitis in non-patients. I will provide a.
課題を解決するための手段  Means for solving the problem
[0006] 本発明者らはこれらの課題を解決すべく鋭意検討を進めた結果、ストレプトコッカス [0006] As a result of diligent studies to solve these problems, the present inventors have found that Streptococcus
'ミュータンス菌の全菌体又は菌体成分に対する抗体と崩壊性研磨剤とを用いること により歯肉炎改善又は予防効果を顕著に増進できることを見出し、本発明を完成さ せた。即ち、本発明は以下のものを提供する。  'It was found that the improvement or prevention effect of gingivitis can be remarkably enhanced by using an antibody against a whole microbial cell or a bacterial cell component of mutans and a disintegrating abrasive, and the present invention has been completed. That is, the present invention provides the following.
(1) ストレプトコッカス'ミュータンス菌の全菌体又は菌体成分に対する抗体と崩壊 性研磨剤とを含む歯肉炎改善剤又は予防剤。  (1) A gingivitis ameliorating agent or preventive agent comprising an antibody against a whole cell or a cell component of Streptococcus mutans and a disintegrating abrasive.
(2) ストレプトコッカス'ミュータンス菌の全菌体又は菌体成分で免疫されたゥシの初 乳組成物と崩壊性研磨剤とを含む歯肉炎改善剤又は予防剤。  (2) A gingivitis ameliorating agent or preventive agent comprising a colostrum colostrum composition immunized with whole cells or components of Streptococcus mutans and a disintegrating abrasive.
(3) 初乳組成物の含有量が該歯肉炎改善剤又は予防剤の総重量に対して 0. 01 一 10重量%である、 (2)の歯肉炎改善剤又は予防剤。  (3) The gingivitis improving or preventing agent according to (2), wherein the content of the colostrum composition is 0.01 to 10% by weight with respect to the total weight of the gingivitis improving or preventing agent.
(4) 菌体成分がストレプトコッカス'ミュータンス菌の細胞壁画分,線維状構造画分, 線毛成分画分,ダルコシルトランスフエレース画分、プロテイン抗原画分、又はそれら の組み合わせである、 (2)又は(3)の歯肉炎改善剤又は予防剤。  (4) The cell component is a cell wall fraction, a fibrous structure fraction, a pilus component fraction, a darcosyltransferase fraction, a protein antigen fraction, or a combination thereof of Streptococcus mutans, (2 ) Or (3) gingivitis improving agent or preventive agent.
(5) ストレプトコッカス'ミュータンス菌がヒト型ストレプトコッカス'ミュータンス菌又は その突然変異体であり、その血清型が c, d, e, f又は g型である、(1)一 (4)の何れか の歯肉炎改善剤又は予防剤。  (5) Streptococcus mutans is a human-type Streptococcus mutans or a mutant thereof, and its serotype is c, d, e, f, or g, (1) one of (4) An agent for improving or preventing gingivitis.
(6) 崩壊性研磨剤が崩壊性シリカゲルを含む、(1) (5)の何れかの歯肉炎改善剤 又は予防剤。  (6) The gingivitis improving agent or preventing agent according to any one of (1) and (5), wherein the disintegrating abrasive comprises disintegrating silica gel.
(7) 該歯肉炎改善剤又は予防剤の pHが 4-10の範囲にある、 (1) (6)の何れの 歯肉炎改善剤又は予防剤。  (7) The gingivitis improving agent or preventing agent according to any one of (1) and (6), wherein the pH of the gingivitis improving agent or preventing agent is in the range of 4-10.
発明を実施するための最良の形態  BEST MODE FOR CARRYING OUT THE INVENTION
[0007] 本発明の歯肉炎改善剤又は予防剤は、ストレプトコッカス'ミュータンス菌の全菌体 又は菌体成分に対する抗体と崩壊性研磨剤とを含む。ここで、ストレプトコッカス 'ミュ 一タンス菌には、突然変異体も含まれる。 [0008] ストレプトコッカス'ミュータンス菌の全菌体又は菌体成分に対する抗体は、ポリクロ ーナル抗体であってもモノクローナル抗体であってもよぐ各種公知の製造方法で製 造することが出来る。例えば、ストレプトコッカス'ミュータンス菌の全菌体又は菌体成 分で動物を免疫し、その動物の分泌物又は組織から抗体を得てもよい。該抗体を含 む好ましい組成物としては、抗原としてストレプトコッカス'ミュータンス菌の全菌体又 は菌体成分を用いて免疫されたゥシの母乳から得られる組成物が挙げられる。中で も、初乳組成物が好ましい。 [0007] The gingivitis improving agent or preventive agent of the present invention comprises an antibody against a whole cell or a cell component of Streptococcus mutans and a disintegrating abrasive. Here, Streptococcus mutans bacteria include mutants. [0008] The antibody against the whole cell or cell component of Streptococcus mutans can be produced by various known production methods, whether it is a polyclonal antibody or a monoclonal antibody. For example, an animal may be immunized with all or a cell component of Streptococcus mutans, and an antibody may be obtained from the secretion or tissue of the animal. A preferred composition containing the antibody includes a composition obtained from breast milk of rush immunized using whole cells or components of Streptococcus mutans as an antigen. Among them, a colostrum composition is preferable.
[0009] 本明細書で初乳とは、分娩後 24時間以内に採取された乳を指し、初乳組成物とは 該初乳から分離された組成物、該初乳を加工して得られた組成物、及び初乳自体を 指す。ゥシ等の動物の免疫は、分娩前 1ヶ月一 3ヶ月以内にストレプトコッカス'ミュー タンス菌の全菌体又は菌体成分を用いて行う。  [0009] As used herein, colostrum refers to milk collected within 24 hours after delivery, and colostrum composition is a composition separated from the colostrum, obtained by processing the colostrum. Composition, and colostrum itself. Immunization of animals such as sushi is carried out using whole cells or components of Streptococcus mutans within one to three months before delivery.
[0010] 初乳組成物は液状であっても固形状であってもよレ、。固形状の組成物としては、初 乳をフリーズドライ法により粉末状としたものが挙げられる。初乳組成物の製造方法に は、製剤化方法として知られた各種の方法を用いることができる。初乳組成物は、歯 垢の蓄積を防止、軽減するだけでなぐ口腔内の皮膚を活性化する効果を有すると ち考えられる。  [0010] The colostrum composition may be liquid or solid. Examples of the solid composition include those obtained by converting colostrum into a powder form by freeze drying. Various methods known as formulation methods can be used for the production method of the colostrum composition. The colostrum composition is considered to have an effect of activating the skin in the oral cavity as well as preventing and reducing plaque accumulation.
[0011] ストレプトコッカス'ミュータンス菌に特に制限はなぐ各種公知の菌が使用できる。  [0011] Various known bacteria that are not particularly restricted by Streptococcus mutans can be used.
中でも、ヒト型ストレプトコッカス'ミュータンス菌及びその突然変異体が好ましぐ血清 型が c, d, e, f、又は g型の菌株がより好ましぐ人の口腔内に多在する c型に属する 菌株がさらに好ましい。  Among them, serotypes preferred by human Streptococcus mutans and mutants thereof are c-types present in the oral cavity of people who prefer c, d, e, f, or g type strains. More preferably, the strain belongs to.
[0012] ストレプトコッカス'ミュータンス菌には、各種公知の培養及び前処理を行ってもよい [0012] Streptococcus mutans may be subjected to various known cultures and pretreatments.
。例えば、 BHI培地の透析外液を培地として使用し、生育した菌を洗浄後ホルマリン 処理したものを使用し得る。 . For example, an externally dialyzed solution of BHI medium can be used as the medium, and the grown bacteria can be washed and then treated with formalin.
[0013] 菌体成分としては、細胞壁画分、線維状構造画分、線毛成分画分、グノレコシルトラ ンスフヱレース(GTF)画分、プロテイン抗原画分、およびこれらの組み合わせが挙げ られる。各画分は、各種公知の方法によって得ることができる。 [0013] Examples of the bacterial cell component include a cell wall fraction, a fibrous structure fraction, a pilus component fraction, a gnolecosyltransferase (GTF) fraction, a protein antigen fraction, and combinations thereof. Each fraction can be obtained by various known methods.
[0014] 初乳組成物を使用する場合、歯肉炎改善剤又は予防剤の総重量に対する初乳組 成物の量は、 0. 01wt%以上、好ましくは lwt%以上、より好ましくは 2wt%以上であ り、 30wt%以下、好ましくは 20wt%以下である。上記範囲未満では初乳の効果が 充分に得られない場合があり、上記範囲を超えると経済的でない。 [0014] When a colostrum composition is used, the amount of colostrum composition relative to the total weight of the gingivitis improving agent or preventive agent is 0.01 wt% or more, preferably 1 wt% or more, more preferably 2 wt% or more. In Therefore, it is 30 wt% or less, preferably 20 wt% or less. If it is less than the above range, the effect of colostrum may not be sufficiently obtained, and if it exceeds the above range, it is not economical.
[0015] 本発明の歯肉炎改善剤又は予防剤は、崩壊性研磨剤を含む。ここで崩壊性研磨 剤とは、荷重下での研磨に供した場合に平均粒径が減少する研磨剤を指す。崩壊 性研磨剤は、歯茎や歯肉を過度に刺激及び摩滅せずに歯垢を除去するだけでなく 、抗体の効果発現を増進しうる。  [0015] The gingivitis improving or preventing agent of the present invention contains a disintegrating abrasive. Here, the disintegrating abrasive refers to an abrasive whose average particle diameter decreases when it is subjected to polishing under a load. Disintegrating abrasives not only remove plaque without excessively irritating and abrading the gums and gums, but can also enhance the expression of antibody effects.
[0016] 崩壊性研磨剤の材料としては、結晶質シリカゲル、第 2リン酸カルシウム · 2水和物、 第 2リン酸カルシウム.無水物、第 1リン酸カルシウム、第 3リン酸カルシウム、炭酸カル シゥム、ピロリン酸カルシウム、不溶性メタリン酸ナトリウム、アルミノシリケート、酸化ァ ルミ二ゥム、水酸化アルミニウム、第 3リン酸マグネシウム、炭酸マグネシウム、硫酸マ グネシゥム、酸化チタン、及び炭素が挙げられる。これらは単独で使用してもよぐ 2 種類以上を混合して使用してもよい。これらの材料は、多孔質であることが好ましい。  [0016] Materials for the disintegrating abrasive include crystalline silica gel, dibasic calcium phosphate dihydrate, dibasic calcium phosphate, anhydrous, monobasic calcium phosphate, tribasic calcium phosphate, calcium carbonate, calcium pyrophosphate, insoluble metaphosphate Examples include sodium, aluminosilicate, aluminum oxide, aluminum hydroxide, tribasic magnesium phosphate, magnesium carbonate, magnesium sulfate, titanium oxide, and carbon. These may be used alone or in combination of two or more. These materials are preferably porous.
[0017] 崩壊性研磨剤の初期の平均粒子径は 9一 100 /i mの範囲にあることが好ましい。  [0017] The initial average particle size of the disintegrating abrasive is preferably in the range of 9 1 100 / im.
荷重下で研磨後の平均粒径に特に制限はなぐ本発明の剤の使用態様に応じて選 択される。例えば、荷重 600g下でのブラッシング 200秒後に平均粒子径が 0.1— 2 μ ηιの範囲にある粒子;初期の平均粒子径が 9一 100 /i mの範囲にあり、荷重 600g 下でのブラッシング 10秒後に平均粒子径が 0.5— 50 μ mにある粒子;を使用するこ とがでさる。  The average particle size after polishing under load is not particularly limited, and is selected according to the use mode of the agent of the present invention. For example, a particle with an average particle size in the range of 0.1-2 μηι after 200 seconds of brushing under a load of 600 g; an initial average particle size of 9 to 100 / im, and brushing under a load of 600 g for 10 seconds Later, particles with an average particle size of 0.5-50 μm can be used.
[0018] 本明細書で、平均粒子径及び粒度分布は、レーザー回折及びレーザー散乱法に 基づいて測定される値で表記する。 「荷重 600gでのブラッシング」とは、歯ブラシに 本発明の剤を 0. 5g塗布し、 300mmの幅を 1分間あたり 200ストロークという条件下 で 600gの荷重をかけてブラッシングを行うことをレ、う。  In this specification, the average particle size and the particle size distribution are expressed as values measured based on laser diffraction and laser scattering methods. “Brushing at a load of 600 g” means that 0.5 g of the agent of the present invention is applied to a toothbrush and brushing is performed with a load of 600 g under the condition of a 300 mm width and 200 strokes per minute. .
[0019] 歯肉炎改善剤又は予防剤の総重量に対する崩壊性研磨剤の量は、 5wt%以上、 好ましくは 10wt°/o、 95wt%以下、好ましくは 60wt%以下である。 [0019] The amount of the disintegrating abrasive with respect to the total weight of the gingivitis improving agent or preventive agent is 5 wt% or more, preferably 10 wt ° / o , 95 wt% or less, preferably 60 wt% or less.
本発明の歯肉炎改善剤又は予防剤では、崩壊性研磨剤は、荷重をかけて使用す る過程で徐々に崩壊することにより、優れた効果をもたらすと考えられる。つまり、歯 肉炎改善剤又は予防剤を歯磨として使用する場合、歯磨き開始時には比較的大き な粒径を有するため大きな汚れを効率的に除去することができる。さらに歯磨きを続 けると細部の汚れが問題となるところ、荷重下で粒子が崩壊して粒径が小さくなるた め、細部の汚れの除去に効果的な形状となる。このように、粒径の経時的変化は、 口 腔内の汚れ及び歯垢の除去に有用である。さらに崩壊性研磨剤が多孔質である場 合、歯磨きを続けると粒子が崩壊して比表面積も増大するため、 口腔内の汚れ、歯 垢、悪臭成分、色素等を効率よく吸収し除去しうる。 In the gingivitis improving agent or preventive agent of the present invention, the disintegrating abrasive is considered to bring about an excellent effect by gradually disintegrating in the process of using a load. That is, when a gingivitis improving agent or preventive agent is used as a toothpaste, since it has a relatively large particle size at the start of toothbrushing, large dirt can be efficiently removed. Continue brushing teeth However, when fine particles become dirty, the particles become disintegrated under load and the particle size becomes small, so that the shape becomes effective for removing fine particles. Thus, the change in particle size over time is useful for removing dirt and plaque in the mouth. Furthermore, if the disintegrating abrasive is porous, the particles will disintegrate and the specific surface area will increase if you continue brushing your teeth, so that you can efficiently absorb and remove dirt, plaque, malodorous components, pigments, etc. in the oral cavity. .
[0020] 本発明の歯肉炎改善剤又は予防剤は、本発明の効果を阻害しない範囲で、歯垢 の除去に有効なその他の成分;ゲル化剤及び溶媒などのキャリア;界面活性剤;甘味 料;着色料;香料;防腐剤;などの各種公知の成分を含んでもょレ、。  [0020] The gingivitis ameliorating agent or preventive agent of the present invention includes other components effective for removing plaque within a range not inhibiting the effects of the present invention; carriers such as gelling agents and solvents; surfactants; It contains various known ingredients such as coloring materials, coloring agents, fragrances, preservatives, and the like.
[0021] 抗体及び崩壊性研磨剤以外の有効成分としては、アラントイン、 ε 一アミノカプロン 酸、トラネキサム酸、ァズレン、ビタミン Cや Εなどのビタミン類、生薬抽出物などが挙 げられる。ゲル化剤としては、カルボキシメチルセルロースナトリウム、メチルセルロー ス、カルボキシメチルヒドロキシェチルセルロースナトリウム、ヒドロキシェチルセル口 ース、アルギン酸ナトリウム、カラギーナン、アラビアガム、キサンタンガム、トラガカント ガム、カラャガム、ポリビニルアルコール、ポリアクリル酸ナトリウム、カルボキシビ二ノレ ポリマー及びポリビュルピロリドン等が挙げられる。ゲルィ匕剤の含有量は、本発明の 剤の総重量に対して、通常 0. 3— 5wt%である。溶媒としては、水、エタノール等が 挙げられる。界面活性剤としては、ァニオン系,ノニオン系,カチオン系,両性イオン 系の界面活性剤が挙げられる。甘味料としては、サッカリンナトリウム、ステビォサイド 、ネオヘスペリジルジヒドロカルコン、グリチルリチン、ペリラルチン、 p—メトキシシンナ ミックアルデヒドなどの甘味剤が挙げられる。香料としては、ペパーミント、スペアミント 等の精油、 1一メントール、カルボン、オイゲノール、ァネトールが挙げられる。  [0021] Active ingredients other than antibodies and disintegrating abrasives include allantoin, ε-monoaminocaproic acid, tranexamic acid, azulene, vitamins such as vitamin C and sputum, and herbal medicine extracts. Gelling agents include sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylhydroxyethylcellulose, hydroxyethylcellulose, sodium alginate, carrageenan, gum arabic, xanthan gum, tragacanth gum, carragham gum, polyvinyl alcohol, polyacrylic. Examples thereof include sodium acid, carboxybinole polymer, and polybulurpyrrolidone. The content of the gelling agent is usually 0.3-5 wt% with respect to the total weight of the agent of the present invention. Examples of the solvent include water and ethanol. Surfactants include anionic, nonionic, cationic, and zwitterionic surfactants. Examples of the sweetener include sweeteners such as saccharin sodium, stevioside, neohesperidyl dihydrochalcone, glycyrrhizin, perilartine, and p-methoxycinnamic aldehyde. Examples of the fragrances include essential oils such as peppermint and spearmint, 1 menthol, carvone, eugenol, and vanitol.
[0022] 本発明の歯肉炎改善剤又は予防剤の剤形に特に制限はなぐクリーム剤、ペースト 剤、錠剤、カプセル剤、散剤、顆粒剤等の固形剤の形状であってもよぐ溶液剤、懸 濁剤、乳剤等の液剤の形状であってもよい。具体的には、本発明に係る歯肉炎改善 剤又は予防剤は、練歯磨、粉歯磨、液状歯磨等の歯磨類;マウスゥォッシュ;口腔内 パスタ;歯肉マッサージクリーム;うがレ、用発泡錠剤等の錠剤;トローチ;チュ一/ fンガ ム、アイスクリーム、ホイップクリームなどの食品;などの各種の形態で提供される。使 用目的及び使用態様に応じて、初乳組成物及び崩壊性研磨剤の量、並びに、これ ら以外の成分の種類及び量が選択される。 [0022] The dosage form of the gingivitis improving agent or the preventive agent of the present invention is not particularly limited. The solution may be in the form of a solid preparation such as a cream, paste, tablet, capsule, powder, granule or the like. It may be in the form of a liquid agent such as a suspension or emulsion. Specifically, the gingivitis improving agent or preventive agent according to the present invention includes dentifrice such as toothpaste, powder dentifrice, liquid dentifrice, etc .; mouthwash; intraoral pasta; gingival massage cream; It is provided in various forms such as tablets; lozenges; foods such as chewy / fungam, ice cream and whipped cream. Depending on the purpose of use and mode of use, the amount of colostrum composition and disintegrating abrasive, and Other types and amounts of ingredients are selected.
[0023] 本発明の歯肉炎改善剤又は予防剤は、剤型に応じて適切な容器に保存され、使 用に供される。本発明の歯肉炎改善剤又は予防剤が固形剤の場合、例えば練歯磨 、粉歯磨、マッサージクリーム等の形態にある場合、好ましい収容容器として、プラス チックチューブやアルミニウム箔ラミネートチューブ等の形状が可変なプラスチック容 器;アルミニウムチューブ等の金属容器;が挙げられる。本発明の歯肉炎改善剤又は 予防剤が液剤の場合、例えば液状歯磨、マウスゥォッシュの場合、 PET容器等のプ ラスチック容器に収容してもよい。収容容器としては、遮光性容器が好ましい。  [0023] The gingivitis improving agent or the preventive agent of the present invention is stored in an appropriate container according to the dosage form and is used. When the gingivitis improving agent or preventive agent of the present invention is a solid agent, for example, when it is in the form of a toothpaste, a toothpaste, a massage cream, etc., the shape of a plastic tube, an aluminum foil laminate tube or the like is variable as a preferable container. Plastic containers; metal containers such as aluminum tubes. When the gingivitis improving agent or preventive agent of the present invention is a liquid agent, for example, in the case of liquid dentifrice or mouthwash, it may be contained in a plastic container such as a PET container. As the container, a light-shielding container is preferable.
[0024] 本発明の歯肉炎改善剤又は予防剤が液剤又はペースト剤である場合、その pHは 必ずしも制限されなレ、が、典型的には pH4以上、好ましくは 5以上、より好ましくは 5. 5以上であり、 10以下、好ましくは 9以下、より好ましくは 7. 5以下である。  [0024] When the gingivitis improving agent or preventive agent of the present invention is a solution or paste, the pH is not necessarily limited, but is typically pH 4 or higher, preferably 5 or higher, more preferably 5. It is 5 or more, 10 or less, preferably 9 or less, more preferably 7.5 or less.
実施例  Example
[0025] 以下、実験例及び実施例を示し、本発明を具体的に説明するが、これら実施例に 制限されるものではない。  [0025] The present invention will be specifically described below with reference to experimental examples and examples, but the present invention is not limited to these examples.
〔実験例 1〕  (Experiment 1)
下記の組成のペースト剤を調製した。抗体は初乳に含まれるものを用レ、、崩壊性研 磨剤として崩壊性シリカゲルを用いた。初乳組成物は、分娩後 24時間以内に採取し たゥシの乳を、フリーズドライ製法により粉末化して得た。ゥシは、予めストレプトコッカ ス 'ミュータンス菌で免疫した。  A paste having the following composition was prepared. The antibody contained in colostrum was used, and disintegrating silica gel was used as a disintegrating abrasive. Colostrum composition was obtained by pulverizing ushi milk collected within 24 hours after delivery by freeze-drying. Usushi was previously immunized with Streptococcus mutans.
[0026] 初乳組成物 10. 0重量% [0026] Colostrum composition 10.0% by weight
崩壊性シリカゲル (調製時の初期平均粒子径: 30 μ m、  Disintegrating silica gel (initial average particle size at the time of preparation: 30 μm,
荷重 600g下でのブラッシング 200秒後の平均粒子径: 1 μ m)  (Brushing under 600g load, average particle size after 200 seconds: 1 μm)
10. 0重量%  10.0% by weight
ポリオキシエチレンポリオキシプオビレンブロック共重合体(平均分子量)  Polyoxyethylene polyoxypouylene block copolymer (average molecular weight)
20. 0重量%  20. 0% by weight
ラウリル硫酸ナトリウム 0. 2重量%  Sodium lauryl sulfate 0.2% by weight
グリセリン 20. 0重量%  Glycerin 20.0% by weight
ゼラチン 0. 1重量% サッカリンナトリウム 0. 5重量% Gelatin 0.1% by weight Saccharin sodium 0.5% by weight
メチルパラベン 0. 3重量%  Methylparaben 0.3 wt%
香料(卜メントール) 1. 0重量%  Fragrance (Menthol) 1.0% by weight
イオン交換水 37. 9重量%  Ion-exchanged water 37. 9% by weight
計 100. 0重量%  Total 10.0% by weight
〔比較例 1〕  (Comparative Example 1)
初乳糸且成物を、ストレプトコッカス'ミュータンス菌で免疫しなかった通常のゥシの乳 に由来する成分に変更した点を除き、実施例 1と同様に下記の組成のペースト剤を 調製した。  A paste having the following composition was prepared in the same manner as in Example 1 except that the colostrum and adult composition was changed to a component derived from normal ushi milk that was not immunized with Streptococcus mutans. .
[0027] ミルク成分 (通常のゥシの乳をフリーズドライ製法により粉末化した。 )  [0027] Milk component (Normal ushi milk was pulverized by freeze-drying)
10. 0重量%  10.0% by weight
崩壊性シリカゲル (調製時の初期平均粒子径: 30 μ m、  Disintegrating silica gel (initial average particle size at the time of preparation: 30 μm,
荷重 600g下でのブラッシング 200秒後平均粒子径: 1 μ m)  (Brushing under 600g load 200 seconds average particle size: 1 μm)
10. 0重量%  10.0% by weight
ポリオキシエチレンポリオキシプオビレンブロック共重合体(平均分子量)  Polyoxyethylene polyoxypouylene block copolymer (average molecular weight)
20. 0重量%  20. 0% by weight
ラウリル硫酸ナトリウム 0. 2重量%  Sodium lauryl sulfate 0.2% by weight
グリセリン 20. 0重量%  Glycerin 20.0% by weight
ゼラチン 0. 1重量%  Gelatin 0.1% by weight
サッカリンナトリウム 0. 5重量0 /0 Sodium saccharin 0.5 weight 0/0
メチルパラベン 0. 3重量%  Methylparaben 0.3 wt%
香料(卜メントール)  Fragrance (salmon menthol)
イオン交換水 37. 9重量%  Ion-exchanged water 37. 9% by weight
計 100. 0重量%  Total 10.0% by weight
〔比較例 2〕  (Comparative Example 2)
崩壊性シリカゲルを難崩壊性シリカゲルに変更した点を除き、比較例 1と同様にし て下記の組成のペースト剤を調製した。  A paste having the following composition was prepared in the same manner as in Comparative Example 1 except that the disintegrating silica gel was changed to a hardly disintegrating silica gel.
[0028] ミルク成分 通常のゥシの乳をフリーズドライ製法により粉末化した。 ) 10. 0重量% Milk component Ordinary ushi milk was pulverized by freeze-drying. ) 10.0% by weight
難崩壊性シリカゲル (調製時の初期平均粒子径: 30 / m) 10. 0重量% ポリオキシエチレンポリオキシプォピレンブロック共重合体(平均分子量)  Hardly disintegrating silica gel (initial average particle size at the time of preparation: 30 / m) 10.0% by weight polyoxyethylene polyoxypropylene block copolymer (average molecular weight)
20. 0重量%  20. 0% by weight
ラウリル硫酸ナトリウム 0. 2重量%  Sodium lauryl sulfate 0.2% by weight
20. 0重量%  20. 0% by weight
ゼラチン 0. 1重量%  Gelatin 0.1% by weight
0. 5重量%  0.5% by weight
メチルパラベン 0. 3重量%  Methylparaben 0.3 wt%
香料ひ-メントール)  Fragrance-menthol)
イオン交換水 37. 9重量%  Ion-exchanged water 37. 9% by weight
計 100. 0重量%  Total 10.0% by weight
〔比較例 3〕  (Comparative Example 3)
崩壊性シリカゲルを難崩壊性シリカゲルに変更した点を除き、実施例 1と同様にし て下記の組成のペースト剤を調製した。  A paste having the following composition was prepared in the same manner as in Example 1 except that the disintegrating silica gel was changed to a hardly disintegrating silica gel.
初乳組成物 10. 0重量%  Colostrum composition 10.0% by weight
難崩壊性シリカゲル (調製時の初期  Difficult silica gel (Initial preparation)
平均粒子径: 30 μ m) 10. 0重量%  (Average particle size: 30 μm) 10. 0% by weight
ポリオキシエチレンポリオキシプオビレンブロック共重合体(平均分子量)  Polyoxyethylene polyoxypouylene block copolymer (average molecular weight)
20. 0重量%  20. 0% by weight
ラウリル硫酸ナトリウム 0. 2直コ  Sodium lauryl sulfate 0.2
20. 0重量?  20. 0 weight?
ゼラチン 0. 1重量  Gelatin 0.1 weight
サッカリンナトリウム 0. 5重邐  Saccharin sodium 0.5
メチルパラベン 0. 3重』  Methylparaben 0.3.
香料 0-メントール)  Fragrance 0-menthol)
イオン交換水 37. 9直  Ion-exchanged water 37.9 straight
計 100. 0重量% [評価例 1] Total 10.0% by weight [Evaluation Example 1]
歯肉炎患者各 2名に、上記のペースト剤を歯磨き剤として 1週間使用させ、官能試 験を行った。その結果を以下の表 1に示す。  Two patients each with gingivitis were allowed to use the above paste as a dentifrice for 1 week, and a sensory test was conducted. The results are shown in Table 1 below.
[表 1] 表 1 歯肉炎の改善効果  [Table 1] Table 1 Improvement effect of gingivitis
Figure imgf000010_0001
Figure imgf000010_0001
◎ 特に優れている  ◎ Especially excellent
〇 優れている  〇 Excellent
厶 やや効果が見られる  厶 Slight effect
X 効果が見られない  X effect not seen
[0031] 表 1からわかる通り、本発明の歯肉炎改善剤又は予防剤は優れた性能を示す。 [0031] As can be seen from Table 1, the gingivitis improving or preventing agent of the present invention exhibits excellent performance.
産業上の利用可能性  Industrial applicability
[0032] 本発明では、ストレプトコッカス'ミュータンス菌の全菌体又は菌体成分に対する抗 体と崩壊性研磨剤とを組み合わせることにより、それぞれを単独で用いる場合よりも 歯肉炎の改善又は予防効果を増進することができる。さらに、本発明の歯肉炎の改 善又は予防剤は、歯肉炎の患者が使用しても患部に対する刺激が少ないため、長 時間の使用に適している。 [0032] In the present invention, by combining an antibody against a whole cell or a cell component of Streptococcus mutans and a disintegrating abrasive, the effect of improving or preventing gingivitis is improved as compared with the case where each is used alone. Can be improved. Furthermore, the agent for improving or preventing gingivitis of the present invention is suitable for long-time use because there is little irritation to the affected area even when used by gingivitis patients.

Claims

請求の範囲 The scope of the claims
[1] ストレプトコッカス'ミュータンス菌の全菌体又は菌体成分に対する抗体と崩壊性研 磨剤とを含む歯肉炎改善剤又は予防剤。  [1] A gingivitis ameliorating agent or preventive agent comprising an antibody against a whole cell or a cell component of Streptococcus mutans and a disintegrating abrasive.
[2] ストレプトコッカス'ミュータンス菌の全菌体又は菌体成分で免疫されたゥシの初乳 組成物と崩壊性研磨剤とを含む歯肉炎改善剤又は予防剤。  [2] A gingivitis ameliorating agent or preventive agent comprising a colostrum composition of urchin immunized with whole cells or components of Streptococcus mutans and a disintegrating abrasive.
[3] 初乳組成物の含有量が該歯肉炎改善剤又は予防剤の総重量に対して 0. 01— 10 重量%である、請求項 2に記載の歯肉炎改善剤又は予防剤。 [3] The gingivitis improving or preventing agent according to claim 2, wherein the content of the colostrum composition is 0.01 to 10% by weight based on the total weight of the gingivitis improving or preventing agent.
[4] 菌体成分がストレプトコッカス'ミュータンス菌の細胞壁画分,線維状構造画分,線 毛成分画分,ダルコシルトランスフエレース画分、プロテイン抗原画分、又はそれらの 組み合わせである、請求項 2又は 3に記載の歯肉炎改善剤又は予防剤。 [4] The cell component is a cell wall fraction of Streptococcus mutans, a fibrous structure fraction, a pilus component fraction, a darcosyltransferase fraction, a protein antigen fraction, or a combination thereof. The gingivitis improving agent or preventive agent according to 2 or 3.
[5] ストレプトコッカス'ミュータンス菌がヒト型ストレプトコッカス'ミュータンス菌又はその 突然変異体であり、その血清型が c, d, e, f又は g型である、請求項 1一 4の何れかに 記載の歯肉炎改善剤又は予防剤。 [5] The Streptococcus mutans bacterium is a human Streptococcus mutans bacterium or a mutant thereof, and the serotype is c, d, e, f, or g type. The gingivitis improving agent or preventive agent of description.
[6] 崩壊性研磨剤が崩壊性シリカゲルを含む、請求項 1 - 5の何れかに記載の歯肉炎 改善剤又は予防剤。 [6] The gingivitis improving agent or preventive agent according to any one of claims 1 to 5, wherein the disintegrating abrasive contains disintegrating silica gel.
[7] 該歯肉炎改善剤又は予防剤の pHが 4—10の範囲にある、請求項 1-6の何れかに 記載の歯肉炎改善剤又は予防剤。  [7] The gingivitis improving or preventing agent according to any one of claims 1 to 6, wherein the gingivitis improving or preventing agent has a pH in the range of 4-10.
PCT/JP2005/003868 2004-09-30 2005-03-07 Gingivitis remedial or preventive agent WO2006038318A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-286079 2004-09-30
JP2004286079A JP2006096711A (en) 2004-09-30 2004-09-30 Gingivitis ameliorating or preventing agent

Publications (1)

Publication Number Publication Date
WO2006038318A1 true WO2006038318A1 (en) 2006-04-13

Family

ID=36142406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/003868 WO2006038318A1 (en) 2004-09-30 2005-03-07 Gingivitis remedial or preventive agent

Country Status (2)

Country Link
JP (1) JP2006096711A (en)
WO (1) WO2006038318A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520910A (en) * 2008-05-16 2011-07-21 コルゲート・パーモリブ・カンパニー Oral composition and use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61112030A (en) * 1984-11-06 1986-05-30 Lion Corp Preventive for dental caries
JPH01265010A (en) * 1988-04-13 1989-10-23 Taiyo Kagaku Co Ltd Cariostatic and antiperiodontic composition
JPH01299211A (en) * 1988-05-25 1989-12-04 Kao Corp Dentifrice
JPH069356A (en) * 1984-11-06 1994-01-18 Lion Corp Dental caries-preventing agent
JPH0710728A (en) * 1993-06-28 1995-01-13 Lion Corp Composition for oral cavity
JP2002348223A (en) * 2001-05-23 2002-12-04 Kobayashi Pharmaceut Co Ltd Composition for toothpaste
JP2003128529A (en) * 2001-10-25 2003-05-08 Kao Corp Dentifrice

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002104983A (en) * 2000-09-28 2002-04-10 Kobayashi Pharmaceut Co Ltd Anticariogenic agent

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61112030A (en) * 1984-11-06 1986-05-30 Lion Corp Preventive for dental caries
JPH069356A (en) * 1984-11-06 1994-01-18 Lion Corp Dental caries-preventing agent
JPH01265010A (en) * 1988-04-13 1989-10-23 Taiyo Kagaku Co Ltd Cariostatic and antiperiodontic composition
JPH01299211A (en) * 1988-05-25 1989-12-04 Kao Corp Dentifrice
JPH0710728A (en) * 1993-06-28 1995-01-13 Lion Corp Composition for oral cavity
JP2002348223A (en) * 2001-05-23 2002-12-04 Kobayashi Pharmaceut Co Ltd Composition for toothpaste
JP2003128529A (en) * 2001-10-25 2003-05-08 Kao Corp Dentifrice

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520910A (en) * 2008-05-16 2011-07-21 コルゲート・パーモリブ・カンパニー Oral composition and use thereof
US10213627B2 (en) 2008-05-16 2019-02-26 Colgate-Palmolive Company Oral compositions and uses therof

Also Published As

Publication number Publication date
JP2006096711A (en) 2006-04-13

Similar Documents

Publication Publication Date Title
JP4111916B2 (en) Composition for alleviating xerostomia and treating related diseases
AU703912B2 (en) Antimicrobial oral composition
TWI252760B (en) Synergistic antiplaque/antigingivitis oral composition
RU2406522C2 (en) Method of reducing inflammation of oral cavity tissue with application of magnolia extract
CA2690011C (en) Dentifrice compositions for treating xerostomia
JP3854619B2 (en) Oral care compositions containing dicarboxy functionalized polyorganosiloxanes
RU2385709C2 (en) Oral care composition for prevention of dental deposit containing magnolia extract
US6136298A (en) Process for inhibiting S. mutans and caries
KR101992927B1 (en) Toothpaste composition for prevention and improvement of periodontal disease
JP2009517382A (en) Oral care therapeutic and prophylactic compositions
TW201102099A (en) Dentifrice compositions and methods for treating and preventing damage to tooth surfaces
US11918675B2 (en) Oral care compositions
TW201240677A (en) Polymer systems
JPH08510239A (en) Oral composition
TW200927184A (en) Dentifrice composition containing silicone oil beads
CN101132806A (en) Method of reducing oral tissue inflammation using magnolia extract
JP2007131601A (en) Composition for oral cavity
KR100951396B1 (en) Dental composition for antiplaque and antigingivity
KR20170103476A (en) Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract
CA2754213C (en) Desensitizing dentifrice exhibiting dental tissue antibacterial agent uptake
WO2006038318A1 (en) Gingivitis remedial or preventive agent
JP2002193776A (en) Cleaning agent for oral cavity
KR20170103482A (en) Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract
KR101818211B1 (en) Composition for prevention or treatment of oral disease comprising Arctill fructus Extract
KR102562829B1 (en) Composition for prevention or treatment of oral disease comprising Alpinia officinarum Extract

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase